With your own knowledge and the help of the following document:

Document 1 (Title: Signal Transduction Mechanisms in Neuronal Communication): Neurotransmitter receptors represent the fundamental molecular interface mediating chemical neurotransmission through diverse signal transduction pathways with profound implications for neuronal function and pharmacological intervention. Structural and functional classification reveals major receptor categories with distinctive coupling mechanisms determining their signaling effects. Ligand-gated ion channels (ionotropic receptors) directly regulate ion flux through integral membrane channels, allowing rapid signal transduction through altered membrane potential and ionic gradients. Classic examples include nicotinic acetylcholine receptors, GABA-A receptors, and glutamate-gated cation channels mediating fast synaptic transmission. G-protein coupled receptors represent another major category utilizing intracellular second messenger systems for signal amplification and modulation. Adenylyl cyclase-coupled receptors, including beta-adrenergic and dopamine D1 receptors, generate cAMP through Gs protein activation, modulating numerous downstream effectors including protein kinases. Similarly, phospholipase C-coupled receptors, exemplified by muscarinic M1 and alpha-1 adrenergic receptors, activate IP3 and diacylglycerol signaling cascades through Gq protein interactions, regulating intracellular calcium and protein kinase C activity. These metabotropic pathways typically mediate slower, modulatory neurotransmission compared to ionotropic mechanisms. Receptor tyrosine kinases represent a distinct category exemplified by neurotrophic factor receptors, utilizing intrinsic enzymatic activity rather than G-protein coupling. Comprehensive receptor characterization reveals complex interactions between signaling pathways, receptor subtype diversity, regulatory mechanisms, and spatiotemporal signaling dynamics that collectively determine the remarkable complexity of neurotransmitter effects on neuronal function, synaptic plasticity, and overall nervous system activity.
Document 2 (Title: Neuromuscular Junction Disorders: Immunological Mechanisms): Myasthenia gravis (MG) represents the prototypical autoimmune disorder of neuromuscular transmission, characterized by fluctuating skeletal muscle weakness that worsens with sustained activity and improves with rest. The disease results from antibody-mediated attack against components of the postsynaptic membrane at the neuromuscular junction, predominantly targeting the nicotinic acetylcholine receptor (AChR). In approximately 85% of patients with generalized MG, serum antibodies against AChR are detectable. These antibodies, predominantly of the IgG1 and IgG3 subclasses, induce pathological changes through three principal mechanisms: complement-mediated destruction of the postsynaptic membrane, accelerated internalization and degradation of cross-linked receptors, and functional receptor blockade preventing acetylcholine binding. The cumulative effect reduces the efficiency of neuromuscular transmission, with clinical weakness manifesting when transmission fails at a critical proportion of muscle fibers. In seronegative cases, approximately 40% harbor antibodies against muscle-specific kinase (MuSK), a postsynaptic membrane protein involved in AChR clustering. Additional antigenic targets include lipoprotein receptor-related protein 4 (LRP4) and agrin. Clinical manifestations reflect the distribution of affected muscles, with ocular involvement (ptosis and diplopia) representing the initial presentation in approximately 85% of cases. Involvement of bulbar musculature produces dysarthria, dysphagia, and facial weakness, while limb-girdle muscles show characteristic fatigability with sustained or repeated activity. Distinctive features include the predilection for cranial nerve-innervated muscles, diurnal fluctuation with evening worsening, and sparing of pupillary responses. Diagnostic approaches include serological testing, electrophysiological studies demonstrating decremental response to repetitive nerve stimulation, and the edrophonium (Tensilon) test, which produces transient improvement by inhibiting acetylcholinesterase and increasing available acetylcholine at the neuromuscular junction. Management strategies encompass symptomatic treatment with cholinesterase inhibitors, immunomodulation through corticosteroids and steroid-sparing agents, and more targeted approaches including thymectomy, plasmapheresis, and monoclonal antibody therapy.
Document 3 (Title: Pharmacological Management of Male Lower Urinary Tract Symptoms): Benign prostatic hyperplasia (BPH) represents a common condition affecting more than 50% of men over age 60, with progressive prevalence increasing with advancing age. The condition leads to bothersome lower urinary tract symptoms through both static (enlargement-related) and dynamic (tone-related) mechanisms of bladder outlet obstruction. Contemporary pharmacological management targets these distinct pathophysiological components with several medication classes. Alpha-1 adrenergic receptor antagonists act on the dynamic component by blocking sympathetic stimulation of smooth muscle within the prostate and bladder neck, thereby reducing urethral resistance without affecting prostate size. These agents are classified by receptor selectivity and pharmacokinetic properties. Tamsulosin demonstrates preferential affinity for alpha-1A receptors predominantly expressed in prostatic tissue, providing rapid symptom relief with minimal effects on vascular alpha-1B receptors, thereby reducing cardiovascular adverse effects such as orthostatic hypotension. This selective receptor profile makes tamsulosin particularly suitable for elderly patients and those with concurrent cardiovascular conditions. Alternative agents with different mechanisms include 5-alpha reductase inhibitors (finasteride, dutasteride), which address the static component by preventing conversion of testosterone to dihydrotestosterone, thereby reducing prostate volume over 3-6 months. Anticholinergic agents such as oxybutynin target bladder overactivity rather than outlet obstruction, but carry risk of urinary retention in men with significant BPH. Phosphodiesterase-5 inhibitors improve BPH symptoms through mechanisms involving nitric oxide pathways. Vasopressors like midodrine, indicated for orthostatic hypotension, have no role in BPH management and may worsen urinary symptoms through increased smooth muscle tone.

Answer the following list question.
Question: Select the correct statement(s): Neurotransmitter receptors can be coupled:
Options:
1. To an ion channel
2. To adenylcyclase
3. To a tyrosine kinase
4. To a phospholipase C
5. To a membrane transporter

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.